Sensorion Completes Second Cohort Enrollment in OTOF Gene Therapy Clinical Trial
SENS-501 is a gene therapy candidate being developed to treat a form of congenital deafness linked to mutations in the OTOF (otoferlin) gene.
SENS-501 is a gene therapy candidate being developed to treat a form of congenital deafness linked to mutations in the OTOF (otoferlin) gene.
Researchers have restored hearing in mice with ENPP1 deficiency using a novel bone-targeted enzyme replacement therapy, offering hope for treating hearing loss in patients with this rare and often fatal genetic disorder.
Federal funding cuts to hearing health programs and research threaten innovation, access, and outcomes in audiology care, with especially dire consequences for vulnerable populations and early childhood intervention.
Starkey has been named a 2025 Top Workplace in Minnesota by the Star Tribune.
Starkey participated in the 2025 Twin Cities HLAA Walk4Hearing, joining thousands of advocates across the country working to break down barriers and empower people with hearing loss.
A bipartisan group of U.S. senators has reintroduced the Medicare Audiology Access Improvement Act to eliminate barriers preventing Medicare beneficiaries from directly accessing care from audiologists.
In her new role, Wenzel will lead WSA’s Audit Committee, focusing on internal audit oversight and risk management evaluation.
In a new study, gene therapy targeting the OTOF gene significantly restored hearing in children and adults with congenital deafness, with rapid improvement and no serious side effects.
Apprentices and students interested in a career in hearing care can participate in the entire EUHA 2025 event free of charge.